SWTX250117P70000
- 0.00
- 0.000.00%
SpringWorks Therapeutics Newsroom
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $55
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $55 to $63
Buy Rating Affirmed for Springworks Therapeutics: Strong Product Potential and Strategic Growth Outlook
Springworks Therapeutics Down Over 13%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk
SpringWorks Therapeutics To Present At J.P. Morgan Healthcare Conference; Webcast At 2:15 PM ET
Update: Springworks Therapeutics Reports Preliminary Q4, Full-Year 2024 Net Product Revenue
TD Sees 'Some Disappointment' With Lack of SpringWorks Therapeutics M&A News
SpringWorks Therapeutics Shares Are Trading Lower Following Q4 and FY24 Financial Results
SpringWorks Therapeutics | 8-K: SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
SpringWorks Therapeutics Reported Q4 OGSIVEO Revenue Of $61.5M, Cash Balance Of $461.9M
Express News | Rappta Therapeutics : Financials Include a $13 Mln Upfront Payment and Potential Milestones Payments
Express News | SpringWorks Therapeutics Inc - to Seek EU Approval for Ogsiveo, Launch in Germany Mid-2025
Express News | SpringWorks Therapeutics : Preliminary Q4 and 2024 U.S. Net Product Revenue for Ogsiveo Were $61.5 Mln and $172.0 Mln
Express News | Rappta Therapeutics Enters Into a Global License Agreement With SpringWorks Therapeutics for a Pre-Clinical First-in-Class Molecular Glue Targeting Pp2a
Express News | SpringWorks Therapeutics: Expects Cash Position to Fund Operations Through Profitability, Which Co Anticipates Achieving in First Half 2026
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?